Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice

Journal of Clinical Pharmacology

Volumn 55, Issue S3, 2015, Pages S39-S50

  Vande Casteele, Niels ^a   Gils, Ann ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

adalimumab; certolizumab pegol; Crohn's; disease; golimumab; immunogenicity; inflammatory bowel disease; infliximab; personalized medicine; therapeutic drug monitoring; trough level; ulcerative colitis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DRUG ANTIBODY; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR ANTIBODY; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFLAMMATORY BOWEL DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; BLOOD; IMMUNOLOGY; METABOLISM; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DRUG MONITORING; HUMANS; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923359740     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.374     Document Type: Article

References (109)

1. Wang W, Wang EQ, Balthasar JP,. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008; 84 (5): 548-558.
2. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP,. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008; 117 (2): 244-279.
3. Katz LH, Kopylov U, Fudim E, et al. Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodies. Clin Res Hepatol Gastroenterol. Published First Online 5 March 2014. DOI: 10.1016/j.clinre.2014.01.010.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359 (9317): 1541-1549.
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353 (23): 2462-2476.
6. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350 (9): 876-885.
7. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132 (1): 52-65.
8. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012; 142 (2): 257-265.
9. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357 (3): 228-238.
10. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357 (3): 239-250.
11. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014; 146 (1): 85-95.
12. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013; 369 (8): 711-721.
13. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005; 353 (18): 1912-1925.
14. Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S,. Targeting TNF-alpha for the treatment of inflammatory bowel disease. Expert Opin Biol Ther. 2014; 14 (1): 75-101.
15. D'Haens GR, Panaccione R, Higgins PDR, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response[quest]. Am J Gastroenterol. 2011; 106 (2): 199-212.
16. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010; 4 (4): 355-366.
17. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009; 58 (4): 492-500.
18. Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010; 31 (1): 92-101.
19. Lofberg R, Louis EV, Reinisch W, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis. 2012; 18 (1): 1-9.
20. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007; 13 (11): 1323-1332.
21. Nestorov I,. Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl. 2005; 74: 13-18.
22. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003; 124 (7): 1774-1785.
23. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010; 69 (5): 817-821.
24. Takeuchi T, Miyasaka N, Tatsuki Y, et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011; 70 (7): 1208-1215.
25. Katz L, Gisbert JP, Manoogian B, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis. 2012; 18 (11): 2026-2033.
26. Gisbert JP, Panes J,. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009; 104 (3): 760-767.
27. Chowers Y, Sturm A, Sans M, et al. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: Biological roles and effects of TNF and TNF antagonists. J Crohn's Colitis. 2010; 4 (4): 367-376.
28. Lobo ED, Hansen RJ, Balthasar JP,. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004; 93 (11): 2645-2668.
29. Schellekens H,. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005; 20 (Suppl 6): vi-v9.
30. Genovese MC, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 2011; 63 (10): 2854-2864.
31. Colombel JF, Feagan BG, Sandborn WJ, Van Assche G, Robinson AM,. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18 (2): 349-358.
32. Roopenian DC, Akilesh S,. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007; 7 (9): 715-725.
33. Ordas I, Mould DR, Feagan BG, Sandborn WJ,. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012; 91 (4): 635-646.
34. Chapman AP,. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev. 2002; 54 (4): 531-545.
35. Louis E, El Ghoul Z, Vermeire S, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther. 2004; 19 (5): 511-519.
36. Louis EJ, Watier HE, Schreiber S, et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics. 2006; 16 (12): 911-914.
37. Arias MT, Cleynen I, Claes K, et al. The role of FC gamma receptor (FCGR) mutations in the response to infliximab in inflammatory bowel disease. Gastroenterology. 2011; 140 (5): S1.
38. Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009; 65 (12): 1211-1228.
39. Maser EA, Villela R, Silverberg MS, Greenberg GR,. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4 (10): 1248-1254.
40. Dall'Acqua WF, Woods RM, Ward ES, et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol. 2002; 169 (9): 5171-5180.
41. Raghavan M, Bjorkman PJ,. Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol. 1996; 12: 181-220.
42. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008; 30 (4): 523-529.
43. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362 (15): 1383-1395.
44. Brandse JF, Wildenberg ME, de Bruyn JR, et al. P500 Fecal loss of infliximab as a cause of lack of response in severe inflammatory bowel disease. J Crohn's Colitis. 2013; 7: S210.
45. Ternant D, Mulleman D, Degenne D, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit. 2006; 28 (2): 169-174.
46. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F(ab') 2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. 2011; 60 (1): 41-48.
47. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348 (7): 601-608.
48. Van Moerkercke W, Compernolle G, Ackaert C, et al. S31 Mucosal healing in Crohn's disease is associated with high infliximab trough levels. J Crohn's Colitis Suppl. 2010; 4 (1): 30-31.
49. Pariente B, Pineton de Chambrun G, Krzysiek R, et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18 (7): 1199-1206.
50. Wolbink GJ, Voskuyl AE, Lems WF, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005; 64 (5): 704-707.
51. Choy EH, Hazleman B, Smith M, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford). 2002; 41 (10): 1133-1137.
52. van de Putte LB, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis. 2003; 62 (12): 1168-1177.
53. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T,. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006; 54 (12): 3782-3789.
54. Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y,. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis. 2010; 16 (11): 1898-1904.
55. Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods. 2012; 382 (1-2): 177-188.
56. Buurman DJ, Vande Casteele N, Sturkenboom MG, et al. Letter: detection of infliximab levels and anti-infliximab antibodies-comparison of three different assays; authors' reply. Aliment Pharmacol Ther. 2013; 37 (2): 282.
57. Lallemand C, Kavrochorianou N, Steenholdt C, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists. J Immunol Methods. 2011; 373 (1-2): 229-239.
58. Vande Casteele N, Buurman DJ, Sturkenboom MGG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Therapeut. 2012; 36 (8): 765-771.
59. Steenholdt C, Ainsworth MA, Tovey M, et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease. Ther Drug Monit. 2013; 35 (4): 530-538.
60. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998; 41 (9): 1552-1563.
61. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008; 134 (7): 1861-1868.
62. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54 (3): 711-715.
63. Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cezard JP,. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol. 2006; 118 (1): 11-19.
64. Gils A, Vande Casteele N, Poppe R, et al. Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization. Ther Drug Monit. Published First Online 5 June 2014. DOI: 10.1097/FTD.0000000000000074.
65. Aalberse RC, Stapel SO, Schuurman J, Rispens T,. Immunoglobulin G4: an odd antibody. Clin Exp Allergy. 2009; 39 (4): 469-477.
66. Steenholdt C, Svenson M, Bendtzen K, Thomsen OO, Brynskov J, Ainsworth MA,. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011; 34 (1): 51-58.
67. Hart MH, de Vrieze H, Wouters D, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods. 2011; 372 (1-2): 196-203.
68. Patton A, Mullenix MC, Swanson SJ, Koren E,. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods. 2005; 304 (1-2): 189-195.
69. van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D,. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J Immunol Methods. 2010; 362 (1-2): 82-88.
70. Afif W, Loftus EV, Jr., Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010; 105 (5): 1133-1139.
71. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P,. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003; 124 (4): 917-924.
72. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P,. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007; 56 (9): 1226-1231.
73. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004; 2 (7): 542-553.
74. Ainsworth MA, Bendtzen K, Brynskov J,. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol. 2008; 103 (4): 944-948.
75. Breedveld FC,. Therapeutic monoclonal antibodies. Lancet. 2000; 355 (9205): 735-740.
76. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56 (9): 1232-1239.
77. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009; 137 (5): 1628-1640.
78. Baert FJ, Lockton S, Hauenstein S, Singh S, Gils A, Vermeire S,. Sa1247 antibodies to adalimumab predict inflammation in Crohn's patients on maintenance adalimumab therapy. Gastroenterology. 2014; 146 (5): S-242.
79. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014; 146 (1): 96-109.
80. Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011; 9 (8): 670-678.
81. O'Meara S, Nanda KS, Moss AC,. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014; 20 (1): 1-6.
82. Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013; 11 (4): 444-447.
83. Vande Casteele N, Drake K, Hauenstein S, Levesque BG, Singh S, Sandborn W,. Sa1249 infliximab and antibody to infliximab concentrations in 7,613 patients shows indication for testing, association with loss of response and provides new insights into binding characteristics of anti-drug antibodies. Gastroenterology. 2014; 146 (5): S-242.
84. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR,. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010; 59 (1): 49-54.
85. Nanda KS, Cheifetz AS, Moss AC,. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013; 108 (1): 40-47.
86. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. Published First Online 4 March 2014. DOI: 10.1136/gutjnl-2012-304094.
87. Vermeire S, Gabriels F, Ballet V, Vande Casteele N, Van Moerkercke W, Van Assche G, Rutgeerts P, Gils A,. The effect of dose escalation on trough levels in patients who lost response to infliximab. Gut. 2010; 3 (Supplement 3): A81.
88. Mazor Y, Koplov U, Ben Hur, et al. P517 Evaluating Adalimumab drug and antibody levels as predictors of clinical and laboratory response in Crohn's disease patients. J Crohn's Colitis. 2013; 7: S217.
89. Colombel JF, Sandborn WJ, Allez M, et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014; 12 (3): 423-431.
90. Cleynen I, Vermeire S,. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012; 9 (9): 496-503.
91. Reinisch W, Feagan BG, Rutgeerts PJ, et al. 566 Infliximab concentration and clinical outcome in patients with ulcerative colitis. Gastroenterology. 2012; 142 (5, Supplement 1): S-114.
92. Atreya R, Neumann H, Neufert C, et al. 473 In vivo molecular imaging using fluorescent anti-TNF antibodies and confocal laser endomicroscopy predicts response to anti-TNF therapy in Crohn's disease. Gastroenterology. 2013; 144 (5): S-85-S-86.
93. Steenholdt C, Palarasah Y, Bendtzen K, et al. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013; 37 (12): 1172-1183.
94. Siegel CA, Melmed GY,. Predicting response to anti-TNF agents for the treatment of Crohn's disease. Therap Adv Gastroenterol. 2009; 2 (4): 245-251.
95. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013; 108 (6): 962-971.
96. Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011; 13 (3): R105.
97. Brandse JF, van der Kleij D, Wolbink G-J,. et al. 786 The pharmacokinetics of infliximab induction therapy in patients with moderate to severe ulcerative colitis. Gastroenterology. 2014; 146 (5): S-134.
98. Baert F, Drobne D, Gils A, et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol. Published First Online 29 January 2014. DOI: 10.1016/j.cgh.2014.01.033.
99. Feagan BG, Singh S, Lockton S, et al. 565 Novel infliximab (IFX) and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn's disease (CD). Gastroenterology. 2012; 142 (5): S-114.
100. Levesque BG, Greenberg GR, Zou G, et al. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther. 2014; 39 (10): 1126-1135.
101. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis. 2013; 7 (9): 736-743.
102. Arias MT, Vande Casteele N, Drobne D, et al. OP10 Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis. J Crohn's Colitis. 2012; 6 (Supplement 1): S5.
103. Drobne D, Bossuyt PJ, Breynaert C, et al. Crohn's disease: infliximab trough levels and CRP during infliximab-immunomodulator combination treatment are associated with clinical outcome after immunomodulator withdrawal. Gastroenterology. 2011; 140 (5, Supplement 1): S-62.
104. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA,. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol. 2011; 46 (3): 310-318.
105. Van Moerkercke W, Ackaert C, Compernolle G, et al. 405 High infliximab trough levels are associated with mucosal healing in Crohn's disease. Gastroenterology. 2010; 138 (5, Supplement 1): S-60.
106. Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014; 12 (1): 80-84.
107. Vande Casteele N, Gils A, Ballet V, et al. OP001 randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: final results of the TAXIT study. United Eur Gastroenterol J. 2013: 138 (1 Suppl): A1.
108. Velayos FS, Kahn JG, Sandborn WJ, Feagan BG,. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013; 11 (6): 654-666.
109. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014; 63 (6): 919-927.